NCT01929421已完成2 期
A Phase II Trial of Salvage Treatment With Gemcitabine and S-1 Combination in Patients With Heavily Treated Advanced Colorectal Cancer.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Response rate
研究概览
简要总结
To assess the efficacy and safety of salvage tratment with Gemcitabine and S-1 Combination in metastatic colorectal cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •non resectable colorectal adenocarcinoma.
- •disease progression during or within 6months after treatment with irinotecan and oxaliplatin contaning regimens.
- •estimated life expectancy of more than 3 months.
- •ECOG status 2 or lower
排除标准
- •other tumor type than adenoarcinoma.
- •presence or history of CNS metastasis.
- •evidence of gastrointestinal bleeding.
研究组 & 干预措施
Gemcitabine/ s-1
Experimental
干预措施: Gemcitabine/S-1 (Drug)
结局指标
主要结局
Response rate
时间窗: 1year
次要结局
- overall survival(1year)
- number of participants with adverse events(1year)
研究者
Hee Kyung Ahn
Assistant Professor
Gachon University Gil Medical Center
研究点 (1)
Loading locations...
相似试验
终止
2 期
Phase II Study of Gemcitabine and TS-1 in Biliary Trat CancerBiliary Tract CancerNCT01171755Samsung Medical Center19
已完成
2 期
Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic CancerPancreatic NeoplasmsNCT00191568Eli Lilly and Company45
Unknown
2 期
A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.Nasopharyngeal CarcinomaNCT02878889Zhejiang Cancer Hospital53
暂停
1 期
Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic CancerPancreatic CancerNCT00209677Hokkaido Gastrointestinal Cancer Study Group40
已完成
2 期
Phase II study of gemcitabine/S-1 combination therapy in patients with non-resectable advanced biliary tract cancernon-resectable biliary tract cancer or recurrent biliary tract cancer post surgical treatmentJPRN-UMIN000000792Kyoto University Hospital25